RNIN - ETF AI Analysis
Top Page
Bushido Capital US SMID Cap Equity ETF (RNIN)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Energy Holdings
Several energy stocks in the top holdings have shown strong gains this year, helping support the fund’s overall results.
Broad Sector Mix
The ETF spreads its investments across technology, consumer, health care, energy, and other sectors, which can help reduce the impact of weakness in any single industry.
Growing Asset Base
The fund has built a meaningful level of assets under management, suggesting it has attracted investor interest and may offer better trading liquidity than very small ETFs.
Negative Factors
Higher-Than-Average Fees
The expense ratio is on the higher side for an ETF, which means more of the fund’s returns are used to cover costs instead of going to investors.
Recent Short-Term Weakness
The ETF has slipped over the past month, showing that its performance can be choppy over shorter time periods.
Heavy U.S. and SMID-Cap Focus
With almost all assets in U.S. small- and mid-sized companies and very little foreign exposure, the fund is sensitive to moves in the U.S. market and this part of the stock universe.
RNIN vs. SPDR S&P 500 ETF (SPY)
AUM151.95M
RegionNorth America
Expense Ratio0.68%
Beta0.78
IssuerBushido
Inception DateMay 14, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,243
30 Day Avg. Volume5,519
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
38.34Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering81
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RNIN Summary
Bushido Capital US SMID Cap Equity ETF (RNIN) is an actively managed fund that focuses on smaller and mid-sized U.S. companies rather than the big household-name giants, and it does not track a set index. It looks for undervalued businesses across areas like technology, consumer companies, health care, and energy, aiming for long-term growth. Examples of holdings include SM Energy and TG Therapeutics. Someone might invest in RNIN to diversify beyond large caps and potentially benefit from faster-growing smaller companies. However, smaller-company stocks can be more volatile, so the ETF’s price can move up and down more sharply than the overall market.
How much will it cost me?The Bushido Capital US SMID Cap Equity ETF (Ticker: RNIN) has an expense ratio of 0.68%, which means you’ll pay $6.80 per year for every $1,000 invested. This is higher than average because the fund is actively managed, requiring more research and decision-making compared to passively managed ETFs that track an index.
What would affect this ETF?The Bushido Capital US SMID Cap Equity ETF (RNIN) could benefit from positive trends in sectors like Consumer Cyclical, Energy, and Technology, which are heavily weighted in its portfolio and may thrive during periods of economic growth or innovation. However, it may face challenges if interest rates rise, as smaller companies often have higher borrowing costs, or if economic conditions weaken, impacting consumer spending and energy demand. Its focus on U.S. small- and mid-cap stocks also makes it sensitive to domestic economic and regulatory changes.
RNIN Top 10 Holdings
RNIN leans heavily into U.S. small and mid-cap growth stories, with tech, consumer, and health names setting the tone. TD SYNNEX looks like one of the steadier engines, rising on solid earnings and execution, while Crocs and Match Group are also pulling their weight with generally positive momentum. On the flip side, Peloton is still losing steam and Nutex Health’s mixed path, with recent softness after earlier gains, keeps it from being a clear winner. Overall, the fund is diversified across sectors but clearly tilted toward U.S. innovation and consumer-driven growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Oscar Health | 2.12% | $3.22M | $7.06B | 57.60% | 49 Neutral | |
| MannKind | 1.71% | $2.60M | $1.00B | -22.06% | 64 Neutral | |
| TD SYNNEX Corporation | 1.69% | $2.56M | $18.54B | 88.60% | 73 Outperform | |
| TG Therapeutics | 1.66% | $2.53M | $6.09B | 16.26% | 65 Neutral | |
| Visteon | 1.54% | $2.34M | $2.92B | 30.26% | 73 Outperform | |
| Clinigence Holdings | 1.54% | $2.34M | $836.36M | -28.08% | 74 Outperform | |
| Peloton Interactive | 1.52% | $2.32M | $2.24B | -28.29% | 45 Neutral | |
| Catalyst Pharma | 1.52% | $2.31M | $3.82B | 29.74% | 83 Outperform | |
| Netscout Systems | 1.48% | $2.25M | $2.77B | 66.08% | 72 Outperform | |
| PVH | 1.47% | $2.24M | $3.90B | 1.79% | 66 Neutral |
RNIN Technical Analysis
Positive
―
Price Trends
30.11
Positive
29.27
Positive
28.18
Positive
Market Momentum
0.16
Positive
55.19
Neutral
56.16
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RNIN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.09, equal to the 50-day MA of 30.11, and equal to the 200-day MA of 28.18, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 55.19 is Neutral, neither overbought nor oversold. The STOCH value of 56.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNIN.
RNIN Peer Comparison
Comparison Results
Performance Comparison
RNIN
Bushido Capital US SMID Cap Equity ETF
31.05
6.56
26.79%
RSMC
Rockefeller U.S. Small-Mid Cap ETF
―
―
―
MSSM
Morgan Stanley Pathway Small-Mid Cap Equity ETF
―
―
―
GRNJ
Fundstrat Granny Shots US Small- & Mid-Cap ETF
―
―
―
SMIZ
Zacks Small/Mid Cap ETF
―
―
―
NBSM
Neuberger Berman Small-Mid Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents